Fucis 150 mg tablets, No. 1
Composition
Active ingredient: fluconazole;
Each tablet contains 150 mg of fluconazole;
Excipients: lactose monohydrate, microcrystalline cellulose, povidone KZ0, talc, magnesium stearate, sodium starch glycolate (type A), croscarmellose sodium.
Dosage Form
Tablets.
Main physical and chemical properties: white, round tablets with beveled edges and a score line on one side.
Pharmacotherapeutic group
Antifungal agents for systemic use. Triazole derivatives. ATC code J02A C01.
Pharmacological properties
Pharmacodynamics.
Mechanism of action.
Fluconazole is an antifungal agent of the triazole class. Its primary mechanism of action is the inhibition of cytochrome P450-mediated demethylation of fungal 14α-lanosterol, which is an essential step in the biosynthesis of fungal ergosterol. The accumulation of 14-alpha-methylsterols correlates with the subsequent loss of ergosterol through the fungal cell membrane and may be responsible for fluconazole’s antifungal activity. Fluconazole is more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P450 enzyme systems.
Administration of fluconazole at a dose of 50 mg daily for 28 days does not affect plasma testosterone levels in men or endogenous steroid levels in women of reproductive age. Fluconazole at doses ranging from 200 to 400 mg daily has no clinically significant effect on endogenous steroid levels or on the response to ACTH stimulation in healthy male volunteers.
A study of interactions with antipyrine showed that a single or multiple doses of 50 mg of fluconazole do not affect the metabolism of antipyrine.
In vitro susceptibility.
It has been shown that fluconazole exhibits antifungal activity in vitro against the most common Candida species (including Candida albicans, Candida parapsilosis, and Candida tropicalis). Candida glabrata exhibits a wide range of susceptibility to fluconazole, whereas Candida krusei is resistant to fluconazole.
Fluconazole also exhibits activity in vitro against Cryptococcus neoformans and Cryptococcus gattii, as well as against the endemic molds Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, and Paracoccidioides brasiliensis.
Relationship between pharmacokinetic and pharmacodynamic properties.
Animal studies have shown a correlation between the minimum inhibitory concentration (MIC) and efficacy against experimental models of mycoses caused by Candida species. Clinical studies have shown a linear relationship between AUC and the dose of fluconazole (approximately 1:1). There is also a direct, but insufficient, relationship between AUC or dose and a positive clinical response to treatment of oral candidiasis and, to a lesser extent, candidemia. Similarly, treatment of infections caused by strains for which fluconazole exhibits a high MIC is less satisfactory.
Mechanism of Resistance.
Microorganisms of the genus Candida exhibit multiple mechanisms of resistance to azole antifungal agents. Fluconazole exhibits a high MIC against fungal strains possessing one or more resistance mechanisms, which negatively impacts its efficacy in vivo and in clinical practice. In normally susceptible Candida species, the most common mechanism of resistance development involves azole-targeted enzymes responsible for ergosterol biosynthesis. Resistance can also be caused by mutation, increased enzyme production, drug efflux mechanisms, or the development of compensatory pathways.
Cases of Candida spp. superinfection have been reported, caused by species other than Candida albicans, which are often resistant to fluconazole (e.g., Candida krusei, C. auris). Alternative antifungal agents should be used to treat such cases. The mechanisms of resistance have not been fully elucidated in some naturally resistant Candida species (C. krusei) or acquired-resistance species (C. auris).
Breakpoints (according to the recommendations of the European Committee on Antimicrobial Susceptibility Testing).
Based on a review of pharmacokinetic/pharmacodynamic data, in vitro susceptibility, and clinical response, fluconazole breakpoints were established for microorganisms of the genus Candida. These were divided into non-species-specific breakpoints, which were largely determined based on pharmacokinetic/pharmacodynamic information and were independent of species-specific distribution of the minimum inhibitory concentration, and species-specific cut-off values, most commonly associated with infections in humans. These cut-off values are listed below.
| Antifungal Agent | Species-specific cut-off values
S ≤ / R > |
Breakpoints not species-specific
S ≤ / R > |
||||
| Candida albicans | Candida glabrata | Candida krusei | Candidal parapsilosis | Tropical Candida | ||
| Fluconazole | 2/4 | IE |
|
2/4 | 2/4 | 2/4 |
S = sensitive;
R = resistant;
a – non-species-specific cut-off values, which were determined primarily based on pharmacokinetic/pharmacodynamic information and do not depend on species-specific distribution at the minimum inhibitory concentration. They have been studied only in microorganisms that do not have a specific cutoff value;
- susceptibility testing is not recommended, as this type is not a target for drug therapy;
IE – There is insufficient evidence to determine whether this type is a target for drug therapy.
Pharmacokinetics.
The pharmacokinetic properties of fluconazole are similar following intravenous and oral administration.
Absorption.
Fluconazole is well absorbed orally, and its plasma levels and systemic bioavailability exceed 90% of those achieved with intravenous fluconazole. Concomitant food intake does not affect the absorption of the drug when taken orally. Peak plasma concentration is reached 0.5–1.5 hours after administration. Plasma concentration is proportional to the dose. Steady-state concentrations of 90% are reached on days 4–5 with once-daily dosing or on the second day of treatment following a loading dose that is twice the usual daily dose on the first day.
Distribution.
The volume of distribution is approximately equal to the total body fluid volume. Plasma protein binding is low (11–12%).
Fluconazole penetrates well into all studied body fluids. Fluconazole levels in saliva and sputum are similar to plasma concentrations. In patients with fungal meningitis, fluconazole levels in cerebrospinal fluid reach 80% of plasma concentrations.
High concentrations of fluconazole in the skin—higher than in serum—are achieved in the stratum corneum, epidermis, dermis, and sweat. Fluconazole accumulates in the stratum corneum.
At a dose of 50 mg once daily, the concentration of fluconazole was 73 μg/g after 12 days of treatment, and 7 days after the end of treatment, the concentration was still 5.8 μg/g. At a dose of 150 mg once weekly, the concentration of fluconazole on the 7th day of treatment was 23.4 μg/g; 7 days after administration of the next dose, the concentration was still 7.1 μg/g.
The concentration of fluconazole in the nails after 4 months of treatment with 150 mg once a week was 4.05 μg/g in healthy volunteers and 1.8 μg/g in patients with nail disorders; Fluconazole was detected in nail samples 6 months after the end of therapy.
Biotransformation.
Fluconazole is metabolized to a minor extent. Following administration of a dose labeled with radioactive isotopes, only 11% of fluconazole is excreted in the urine in a metabolized form. Fluconazole is a moderate inhibitor of the CYP2C9 and CYP4 isoenzymes and a potent inhibitor of the CYP2C19 isoenzyme.
Elimination.
The plasma half-life of fluconazole is approximately 30 hours. Most of the drug is excreted by the kidneys, and 80% of the administered dose is found unchanged in the urine. The clearance of fluconazole is proportional to creatinine clearance. No circulating metabolites have been detected.
The drug’s long plasma half-life allows for a single-dose regimen in the treatment of vaginal candidiasis, as well as once-weekly dosing for other indications.
Pharmacokinetics in Renal Insufficiency.
In patients with severe renal insufficiency (eGFR < 20 mL/min), the half-life increases from 30 to 98 hours, requiring a dose reduction. Fluconazole is removed by hemodialysis and, to a lesser extent, by peritoneal dialysis. A 3-hour hemodialysis session reduces the plasma concentration of fluconazole by approximately 50%.
Pharmacokinetics during lactation.
Plasma and breast milk concentrations of fluconazole over 48 hours following a single 150-mg dose were evaluated in a pharmacokinetic study involving ten lactating women who had temporarily or permanently discontinued breastfeeding their infants. In breast milk, fluconazole was detected at an average concentration of approximately 98% of the concentration observed in the mother’s blood plasma. Five point two hours after administration, the average peak concentration in breast milk was 2.61 mg/L. The daily dose of fluconazole received by an infant through breast milk (assuming an average milk intake of 150 mL/kg/day), calculated based on an average peak concentration in milk of 0.39 mg/kg/day, is approximately 40% of the dose recommended for < newborns (2 weeks of age), or 13% of the dose recommended for infants for the treatment of mucosal candidiasis.
Pharmacokinetics in children.
Pharmacokinetic parameters in children were evaluated in 5 studies: 2 single-dose studies, 2 multiple-dose studies, and one study involving preterm newborns.
Following administration of fluconazole at doses ranging from 2 to 8 mg/kg in children aged 9 months to 15 years, an AUC of approximately 38 μg·h/mL per 1 mg/kg dose was observed. With multiple doses, the mean plasma half-life of fluconazole ranged from 15 to 18 hours, and the volume of distribution was approximately 880 mL/kg. A longer plasma half-life of fluconazole, approximately 24 hours, was observed following a single dose. This is comparable to the plasma half-life of fluconazole following a single intravenous dose of 3 mg/kg in children aged 11 days to 11 months. The volume of distribution in this age group was approximately 950 mL/kg.
Experience with fluconazole in newborns is limited to pharmacokinetic studies in 12 preterm newborns with a gestational age of approximately 28 weeks. The mean age of the newborn at the time of the first dose was 24 hours (range 9–36 hours), and the mean birth weight was 0.9 kg (range 0.75–1.10 kg). A maximum of 5 intravenous injections of fluconazole at a dose of 6 mg/kg were administered every 72 hours. The mean half-life was 74 hours (44–185) on the first day, then decreased to 53 hours (30–131) on day 7 and to 47 hours (27–68) on day 13. The area under the curve (μg·h/mL) was 271 (173–385) on day 1, increased to 490 (292–734) on day 7, and then decreased to 360 (167–566) on day 13. The volume of distribution (mL/kg) was 1,183 (1,070–1,470) on day 1, increasing to 1,184 (510–2,130) on day 7 and to 1,328 (1,040–1,680) on day 13, respectively.
Pharmacokinetics in Elderly Patients.
In a study involving 22 patients (aged 65 years and older), fluconazole was administered orally at a dose of 50 mg. Ten participants were concurrently taking diuretics. Cmax was 1.54 μg/mL and was reached within 1.3 hours after administration of fluconazole. The mean AUC was 76.4 ± 20.3 μg·h/mL. The mean half-life was 46.2 hours. These pharmacokinetic parameters are higher compared to those in healthy young volunteers. Concomitant use of diuretics had no significant effect on Cmax and AUC. In addition, creatinine clearance (74 mL/min), the percentage of unchanged fluconazole excreted in the urine (0.24 hours, 22%), and the renal clearance of fluconazole (0.124 mL/min/kg) in patients in this age group were lower than in younger volunteers. Thus, changes in pharmacokinetics in elderly patients appear to depend on renal function parameters.
Indications
Fuzis® is indicated for the treatment of the following fungal infections in adults (see the “Pharmacodynamics” section):
- acute vaginal candidiasis, when local therapy is not appropriate;
- candidal balanitis, when local therapy is not appropriate.
Treatment with Fusis® may be initiated before the results of bacteriological testing and other laboratory tests are available; however, once the test results are received, antimicrobial therapy should be adjusted accordingly.
Official recommendations regarding the proper use of antifungal medications should be followed.
Contraindications
- Hypersensitivity to fluconazole, other azole compounds, or any of the drug’s excipients.
- Concomitant use of fluconazole and terfenadine in patients who have received multiple doses of fluconazole at doses of 400 mg/day or higher (based on the results of a multiple-dose interaction study).
- Concomitant use of fluconazole with other drugs that prolong the QT interval and are metabolized by CYP4A4 (e.g., cisapride, astemizole, pimozide, quinidine, and erythromycin). See the sections “Special Warnings and Precautions for Use” and “Interactions with Other Medications and Other Forms of Interaction.”
Interactions with Other Medications and Other Forms of Interaction
Concomitant use of fluconazole and the following drugs is contraindicated.
Cisapride: Cardiac adverse reactions, including paroxysmal ventricular tachycardia, have been reported in patients receiving concomitant treatment with fluconazole and cisapride. Concomitant use of 200 mg of fluconazole once daily and 20 mg of cisapride four times daily resulted in a significant increase in cisapride plasma levels and QT interval prolongation. Concomitant use of fluconazole and cisapride is contraindicated (see the “Contraindications” section).
Terfenadine: Drug interaction studies were conducted in patients taking azole antifungal agents concomitantly with terfenadine, following reports of severe cardiac arrhythmias caused by QTc prolongation. Fluconazole 200 mg daily did not result in QTc prolongation. The use of fluconazole at doses of 400 mg daily or higher significantly increases terfenadine plasma levels when these drugs are used concomitantly. Concomitant use of fluconazole at doses of 400 mg or higher with terfenadine is contraindicated (see the “Contraindications” section). When fluconazole is administered at doses below 400 mg per day concurrently with terfenadine, the patient should be closely monitored.
Astemizole: Concomitant use of fluconazole and astemizole may reduce the clearance of astemizole. The resulting increase in plasma concentrations of astemizole may lead to QT interval prolongation and, in rare cases, to “pirouette”-type paroxysmal ventricular tachycardia. Concomitant use of fluconazole and astemizole is contraindicated (see the “Contraindications” section).
Pimozide: Concomitant use of fluconazole with pimozide may result in inhibition of pimozide metabolism, although no relevant in vitro or in vivo studies have been conducted. Elevated plasma concentrations of pimozide may lead to QT interval prolongation and, in rare cases, to paroxysmal “pirouette” ventricular tachycardia. Concomitant use of fluconazole with pimozide is contraindicated (see the “Contraindications” section).
Quinidine: Concomitant use of fluconazole and quinidine may inhibit quinidine metabolism, although no in vitro or in vivo studies have been conducted. The use of quinidine has been associated with QT interval prolongation and, in rare cases, paroxysmal ventricular tachycardia of the “pirouette” type. Concomitant use of fluconazole with quinidine is contraindicated (see the “Contraindications” section).
Erythromycin: Concomitant use of fluconazole with erythromycin may lead to an increased risk of cardiotoxicity (QT interval prolongation and “pirouette”-type paroxysmal ventricular tachycardia) and, consequently, to sudden coronary death. Concomitant use of fluconazole and erythromycin is contraindicated (see the “Contraindications” section).
Concomitant use of fluconazole and the following medications is not recommended.
Halofantrine: Fluconazole may increase plasma concentrations of halofantrine by inhibiting CYP3A4. Concomitant use of these drugs may potentially lead to an increased risk of cardiotoxicity (QT interval prolongation, “pirouette”-type paroxysmal ventricular tachycardia) and, consequently, sudden cardiac death. The combination of these drugs should be avoided (see the “Special Instructions and Precautions for Use” section).
Concomitant use of fluconazole and the following medications requires caution.
Amiodarone: Concomitant use of fluconazole with amiodarone may lead to QT interval prolongation. Caution should be exercised when fluconazole and amiodarone are used concomitantly, especially when fluconazole is administered at high doses (800 mg).
Concomitant use of fluconazole with the following medications requires caution and dose adjustment.
Effects of Other Medications on Fluconazole.
Concomitant food intake, cimetidine, antacids, and total-body radiation therapy (during bone marrow transplantation) do not have a clinically significant effect on the absorption of fluconazole when administered orally.
Rifampicin: Concomitant use of fluconazole and rifampicin resulted in a 25% decrease in AUC and a 20% reduction in the half-life of fluconazole. Therefore, for patients taking rifampicin, an increase in the dose of fluconazole should be considered.
Hydrochlorothiazide: In a pharmacokinetic interaction study, concomitant multiple doses of hydrochlorothiazide in healthy volunteers receiving fluconazole increased the plasma concentration of fluconazole by 40%. These interaction parameters do not require a change in the dosing regimen of fluconazole in patients receiving concomitant diuretics.
Effect of fluconazole on other medications.
Fluconazole is a moderate inhibitor of the cytochrome P450 (CYP) 2C9 and 3A4 isoenzymes. Fluconazole is a potent inhibitor of the CYP2C19 isoenzyme. In addition to the observed/documented interactions described below, there is a risk of increased plasma concentrations of other metabolized compounds processed by CYP2C9, CYP2C19, and CYP3A4 when used concomitantly with fluconazole. Therefore, such drug combinations should be used with caution; patients should be closely monitored. The inhibitory effect of fluconazole on enzymes persists for 4–5 days after administration due to its long half-life (see the “Contraindications” section).
Alfentanil: Concomitant administration of 400 mg of fluconazole and 20 mcg/kg of alfentanil intravenously is associated with a twofold increase in AUC 10 (possibly due to CYP3A4 inhibition). This necessitates a dose adjustment for alfentanil.
Amitriptyline, nortriptyline: Fluconazole potentiates the effects of amitriptyline and nortriptyline. It is recommended to measure the concentrations of 5-nortriptyline and/or S-amitriptyline at the start of combination therapy and 1 week after its initiation. If necessary, the dose of amitriptyline or nortriptyline should be adjusted.
Amphotericin B: Concomitant administration of fluconazole and amphotericin B to immunocompromised mice resulted in the following: a slight additive antifungal effect in systemic Candida albicans infection, no interaction in intracranial Cryptococcus neoformans infection, and antagonism between these two drugs in systemic Aspergillus fumigatus infection. The clinical significance of these results is unknown.
Anticoagulants: As with other azole antifungal agents, cases of bleeding (hematoma, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported with the concomitant use of fluconazole and warfarin. Concomitant use of fluconazole and warfarin resulted in a twofold increase in prothrombin time, presumably due to inhibition of warfarin metabolism via CYP2C9. Caution is advised. Monitor prothrombin time in patients concurrently taking coumarin anticoagulants or indandione. Anticoagulant dose adjustment may be required.
Short-acting benzodiazepines, such as midazolam and triazolam: administration of fluconazole following oral administration of midazolam resulted in a significant increase in midazolam concentrations and an intensification of psychomotor effects. Concomitant oral administration of 200 mg of fluconazole and 7.5 mg of midazolam resulted in a 3.7-fold and 2.2-fold increase in AUC and half-life, respectively. Oral administration of 200 mg/day of fluconazole and 0.25 mg of triazolam resulted in a 4.4-fold and 2.3-fold increase in the AUC and half-life of triazolam, respectively. Concomitant use of fluconazole and triazolam resulted in potentiation and prolongation of the effects of triazolam.
If a patient receiving fluconazole requires concomitant treatment with benzodiazepines, the dose of benzodiazepines should be reduced, and the patient should be closely monitored.
Carbamazepine: Fluconazole inhibits the metabolism of carbamazepine and causes a 30% increase in serum carbamazepine levels. There is a risk of carbamazepine toxicity. The carbamazepine dose may need to be adjusted depending on its serum concentration and the drug’s effects.
Calcium channel blockers: Some calcium channel blockers (nifedipine, isradipine, amlodipine, verapamil, and felodipine) are metabolized by the CYP3A4 enzyme. Fluconazole has the potential to increase the systemic exposure of calcium channel blockers. Close monitoring for adverse reactions is recommended.
Celecoxib: Concomitant use of fluconazole (200 mg daily) and celecoxib (200 mg) increased the Cmax and AUC of celecoxib by 68% and 134%, respectively. When celecoxib and fluconazole are used concomitantly, it may be necessary to reduce the celecoxib dose by half.
Cyclophosphamide: Concomitant use of cyclophosphamide and fluconazole leads to increased levels of bilirubin and creatinine in serum. These drugs may be used concomitantly, taking into account the potential risk of increased serum bilirubin and creatinine concentrations.
Fentanyl: One fatal case of fentanyl intoxication has been reported due to a possible interaction between fentanyl and fluconazole. Fluconazole significantly delays the elimination of fentanyl. Elevated fentanyl levels may lead to respiratory depression; therefore, the patient must be closely monitored. A dose adjustment of fentanyl may be required.
HMG-CoA reductase inhibitors: Concomitant use of fluconazole and HMG-CoA reductase inhibitors metabolized by CYP3A4 (atorvastatin and simvastatin), or HMG-CoA reductase inhibitors metabolized by CYP2C9 (fluvastatin), increases the risk of myopathy and rhabdomyolysis. If concomitant use of these drugs is necessary, the patient should be closely monitored for symptoms of myopathy and rhabdomyolysis, and creatine kinase levels should be monitored. In the event of a significant increase in creatine kinase levels, HMG-CoA reductase inhibitors should be discontinued if myopathy or rhabdomyolysis is suspected or confirmed.
Ibrutinib: Moderate CYP3A4 inhibitors, such as fluconazole, increase the plasma concentration of ibrutinib and may increase the risk of toxicity. If the drug combination cannot be avoided, the dose of ibrutinib should be reduced to 280 mg once daily to maintain the inhibitor’s effect and ensure continuous clinical monitoring.
Ivacaftor: Concomitant use of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, increased the exposure of ivacaftor 3-fold and that of hydroxymethylivacaftor (M1) 1.9-fold. Patients taking moderate CYP3A inhibitors, such as fluconazole and erythromycin, at the same time are advised to reduce the dose of ivacaftor to 150 mg once daily.
Olaparib: Moderate CYP3A4 inhibitors, such as fluconazole, increase the plasma concentration of olaparib; concomitant use is not recommended. If this combination cannot be avoided, the dose of olaparib should be reduced to 200 mg twice daily.
Immunosuppressants (e.g., cyclosporine, everolimus, sirolimus, and tacrolimus).
Cyclosporine: Fluconazole significantly increases the concentration and AUC of cyclosporine. Concomitant use of fluconazole 200 mg/day and cyclosporine at a dose of 2.7 mg/kg/day resulted in a 1.8-fold increase in the AUC of cyclosporine. These drugs may be used concomitantly, provided that the cyclosporine dose is reduced based on its concentration.
Everolimus: Fluconazole may increase serum concentrations of everolimus due to inhibition of CYP4A4.
Sirolimus: Fluconazole increases sirolimus plasma concentrations, presumably by inhibiting sirolimus metabolism via CYP3A4 and P-glycoprotein. These drugs may be used concomitantly, provided that the sirolimus dose is adjusted based on drug concentration and effect.
Tacrolimus: Fluconazole may increase tacrolimus serum concentrations up to 5-fold when taken orally due to inhibition of tacrolimus metabolism by the CYP3A4 enzyme in the intestine. No significant changes in pharmacokinetics were observed with intravenous administration of tacrolimus. Elevated tacrolimus levels are associated with nephrotoxicity. The oral dose of tacrolimus should be reduced based on tacrolimus concentrations.
Losartan: Fluconazole inhibits the conversion of losartan to its active metabolite (E-31 74), which accounts for most of the angiotensin II receptor antagonism following administration of losartan. Regular monitoring of blood pressure in patients is recommended.
Methadone: Fluconazole may increase serum methadone concentrations. When methadone and fluconazole are used concomitantly, a dose adjustment of methadone may be required.
Nonsteroidal anti-inflammatory drugs (NSAIDs): When used concomitantly with fluconazole, the Cmax and AUC of flurbiprofen increased by 23% and 81%, respectively, compared with flurbiprofen monotherapy. Similarly, when fluconazole was administered concomitantly with racemic ibuprofen (400 mg), the Cmax and AUC of the pharmacologically active isomer S-(+)-ibuprofen were increased by 15% and 82%, respectively, compared with racemic ibuprofen alone.
Fluconazole has the potential to increase the systemic exposure of other NSAIDs metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). Periodic monitoring for NSAID-related adverse reactions and toxicity is recommended. NSAID dose adjustment may be necessary.
Phenytoin: Fluconazole inhibits the metabolism of phenytoin in the liver. Concomitant intravenous administration of 200 mg of fluconazole and 250 mg of phenytoin results in a 75% increase in phenytoin AUC 24 and a 128% increase in Cmin. When these drugs are used concomitantly, serum phenytoin concentrations should be monitored to avoid the development of phenytoin toxicity.
Prednisolone: There has been a reported case in which a patient who had undergone a liver transplant and was receiving prednisolone developed acute adrenal insufficiency after discontinuing a three-month course of fluconazole therapy. Discontinuation of fluconazole presumably caused an increase in CYP3A4 activity, which led to accelerated metabolism of prednisolone. Patients who have been taking fluconazole and prednisolone concomitantly for a prolonged period should be closely monitored to prevent the development of adrenal insufficiency following discontinuation of fluconazole.
Rifabutin: Fluconazole increases the serum concentration of rifabutin, leading to an increase in rifabutin AUC of up to 80%. Cases of uveitis have been reported with the concomitant use of fluconazole and rifabutin. When using this combination of drugs, symptoms of rifabutin toxicity should be monitored.
Saquinavir: Fluconazole increases the AUC and Cmax of saquinavir by approximately 50% and 55%, respectively, due to inhibition of saquinavir’s hepatic metabolism by the CYP3A4 enzyme and inhibition of P-glycoprotein. Interactions between fluconazole and saquinavir/ritonavir have not been studied; therefore, they may be more pronounced. A dose adjustment of saquinavir may be required.
Sulfonylureas: Concomitant use of fluconazole with oral sulfonylurea drugs (chlorpropamide, glibenclamide, glipizide, and tolbutamide) has resulted in prolongation of their half-lives. Frequent monitoring of blood glucose levels is recommended, and the dose of sulfonylurea should be reduced accordingly when used concomitantly with fluconazole.
Theophylline: Administration of fluconazole at a dose of 200 mg for 14 days resulted in an 18% decrease in the mean plasma clearance of theophylline. Patients taking high doses of theophylline or who are at increased risk of theophylline toxicity for other reasons should be monitored for signs of theophylline toxicity. Therapy should be adjusted if signs of toxicity appear.
Tofacitinib: The effect of tofacitinib is enhanced when used concomitantly with drugs that cause moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole). Therefore, it is recommended to reduce the dose of tofacitinib to 5 mg once daily when used in combination with these drugs.
Tolvaptan: The exposure to tolvaptan (a CYP3A4 substrate) increases significantly (200% AUC; 80% Cmax) when co-administered with fluconazole (a moderate CYP3A4 inhibitor) and, consequently, increases the risk of adverse reactions such as increased diuresis, dehydration, and acute renal failure. When used concomitantly, the tolvaptan dose should be reduced as directed, and the patient should be monitored for adverse reactions.
Periwinkle alkaloids: Fluconazole, presumably due to CYP3A4 inhibition, may cause an increase in the plasma concentrations of periwinkle alkaloids (e.g., vincristine and vinblastine), leading to neurotoxic effects.
Vitamin A: It has been reported that a patient receiving both transretinoic acid (the acid form of vitamin A) and fluconazole experienced CNS adverse reactions in the form of a pseudotumor cerebri, which resolved after discontinuation of fluconazole. These drugs may be used concomitantly, but the risk of CNS adverse reactions should be kept in mind.
Voriconazole (an inhibitor of CYP2C9, CYP2C19, and CYP4): Concomitant use of oral voriconazole (400 mg every 12 hours for 1 day, followed by 200 mg every 12 hours for 2.5 days) and oral fluconazole (400 mg on the first day, followed by 200 mg every 24 hours for 4 days) resulted in an increase in voriconazole Cmax and AUCτ by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. It is unknown whether reducing the dose and/or frequency of voriconazole or fluconazole reverses this effect. When voriconazole is administered following fluconazole, patients should be monitored for the development of voriconazole-associated adverse effects.
Zidovudine: Fluconazole increases the Cmax and AUC of zidovudine by 84% and 74%, respectively, due to a reduction in zidovudine clearance of approximately 45% following oral administration. The half-life of zidovudine was also increased by approximately 128% following the combination of fluconazole and zidovudine. Patients using this drug combination should be monitored for zidovudine-related adverse reactions. You may want to consider reducing the zidovudine dose.
Azithromycin: No significant pharmacokinetic interactions were observed with the concurrent oral administration of azithromycin and fluconazole at doses of 1,200 mg and 800 mg, respectively.
Oral contraceptives: Fluconazole 50 mg had no effect on hormone levels, whereas fluconazole 200 mg daily increased the AUC of ethinyl estradiol by 40% and that of levonorgestrel by 24%. This suggests that multiple doses of fluconazole are unlikely to affect the efficacy of combined oral contraceptives.
Ivacaftor: Concomitant use with ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) enhancer, increases the exposure of ivacaftor 3-fold and that of hydroxymethylivacaftor (M1) 1.9-fold. For patients also taking moderate CYP3A inhibitors, such as fluconazole and erythromycin, a reduction in the ivacaftor dose to 150 mg once daily is recommended.
Special Considerations for Use
Dermatophytosis. It is known that when fluconazole is used to treat dermatophytosis in children, it is no more effective than griseofulvin, and the overall efficacy rate is less than 20%. Therefore, fluconazole should not be used to treat dermatophytosis.
Cryptococcosis. There is insufficient evidence of fluconazole’s efficacy for the treatment of cryptococcosis in other sites (e.g., pulmonary cryptococcosis and cutaneous cryptococcosis); therefore, there are no recommendations regarding the dosing regimen for the treatment of such conditions.
Deep-seated endemic mycoses. There is insufficient evidence of the efficacy of fluconazole for the treatment of other forms of endemic mycoses, such as paracoccidioidomycosis, histoplasmosis, and cutaneous-lymphatic sporotrichosis; therefore, there are no dosage recommendations for the treatment of these conditions.
Renal system. In patients with impaired renal function, the drug should be used with caution (see the “Dosage and Administration” section).
Adrenal insufficiency. Ketoconazole is known to cause adrenal insufficiency, and this may also occur with fluconazole, although it is rare. Adrenal insufficiency associated with concomitant treatment with prednisolone is described in the “Effects of Fluconazole on Other Medications” section under “Drug Interactions and Other Forms of Interaction.”
Hepatobiliary system. The drug should be used with caution in patients with impaired liver function. The use of fluconazole has been associated with rare cases of severe hepatotoxicity, including fatalities, primarily in patients with severe underlying medical conditions. In cases where hepatotoxicity was associated with fluconazole use, it was not clearly related to the total daily dose of the drug, duration of therapy, gender, or age of the patient. Fluconazole-induced hepatotoxicity is usually reversible and resolves after discontinuation of therapy.
Patients with abnormal liver function tests while taking fluconazole should be closely monitored for more severe liver damage.
Patients should be informed of symptoms that may indicate serious liver complications (severe asthenia, anorexia, persistent nausea, vomiting, and jaundice). In such cases, fluconazole should be discontinued immediately and a physician consulted.
Cardiovascular system. Some azoles, including fluconazole, are associated with QT interval prolongation on an electrocardiogram. Fluconazole causes QT interval prolongation by inhibiting the flow of ions through inwardly rectifying potassium (ICR) channels.QT prolongation caused by other drugs (e.g., amiodarone) may be exacerbated by inhibition of the cytochrome P450 enzyme CYP3A4. Very rare cases of QT interval prolongation and “pirouette” paroxysmal ventricular tachycardia have been reported with fluconazole use. These reports involved patients with severe disease who had a combination of several risk factors, such as structural heart disease, electrolyte imbalances, and concomitant use of other drugs that affect the QT interval. Patients with hypokalemia and severe heart failure are at increased risk of developing life-threatening ventricular arrhythmias and paroxysmal ventricular tachycardia.
Fluconazole should be used with caution in patients at risk of developing arrhythmias. Concomitant use with drugs that prolong the QTc interval and are metabolized by the cytochrome P450 CYP3A4 enzyme is contraindicated (see the sections “Contraindications” and “Drug Interactions and Other Interactions”).
Halofantrine. Halofantrine is a substrate of the CYP4A4 enzyme and prolongs the QTc interval when used at recommended therapeutic doses. Concomitant use of halofantrine and fluconazole is not recommended (see the “Interactions with Other Medications and Other Forms of Interaction” section).
Dermatological reactions. Exfoliative skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have rarely been reported with fluconazole. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported. Patients with AIDS are more likely to develop severe skin reactions when taking many medications. If a patient with a superficial fungal infection develops a rash that may be related to the use of fluconazole, further use of the drug should be discontinued. If a patient with an invasive/systemic fungal infection develops a skin rash, the patient should be closely monitored, and fluconazole should be discontinued if a bullous rash or erythema multiforme develops.
Hypersensitivity. Anaphylactic reactions have been reported in rare cases (see the “Contraindications” section).
Cytochrome P450. Fluconazole is a moderate inhibitor of the CYP2C9 and CYPZA4 enzymes. Fluconazole is also a moderate inhibitor of the CYP2C19 enzyme. Patients receiving fluconazole concomitantly with drugs that have a narrow therapeutic index and are metabolized by CYP2C9, CYP2C19, and CYP3A4 should be monitored (see the “Drug Interactions and Other Interactions” section).
Terfenadine. Patients should be closely monitored when terfenadine is used concomitantly with fluconazole at a dose of less than 400 mg per day (see the “Contraindications” and “Interactions with Other Medications and Other Forms of Interaction” sections).
Candidiasis. Studies have shown an increased incidence of infections caused by Candida species other than C. albicans.These species often possess intrinsic resistance (e.g., C. krusei and C. auris) or exhibit reduced susceptibility to fluconazole (C. glabrata). Such infections may require alternative antifungal therapy due to treatment failure. Therefore, it is recommended to consider the prevalence of fluconazole resistance among different Candida species.
Inactive Ingredients.
This medication contains lactose. If a patient has a known intolerance to certain sugars, they should consult a doctor before taking this medication.
Pregnancy and lactation.
Pregnancy
According to an observational study, there is an increased risk of spontaneous abortion in women who received fluconazole during the first trimester of pregnancy.
Numerous congenital anomalies have been reported in newborns (including brachycephaly, auricular dysplasia, excessive enlargement of the anterior fontanelle, hip deformity, and humeroradial synostosis) whose mothers took high doses of fluconazole (400 to 800 mg/day) for at least three or more months to treat coccidioidomycosis. A causal relationship between fluconazole use and these cases has not been established.
Animal studies have demonstrated reproductive toxicity.
Routine doses of fluconazole and short-term courses of fluconazole should not be used during pregnancy unless absolutely necessary.
High doses of fluconazole and/or long-term courses of fluconazole should not be used during pregnancy, except for the treatment of life-threatening infections.
Breastfeeding.
Fluconazole is excreted into breast milk and reaches concentrations similar to those in plasma (see the “Pharmacokinetics” section). Breastfeeding may be continued after a single 150 mg dose of fluconazole.
Breastfeeding is not recommended with repeated use of fluconazole or at high doses of fluconazole.
The benefits of breastfeeding for the infant’s development and health should be weighed as well as the mother’s clinical need for Fuzis® and any potential side effects of Fuzis® or the mother’s underlying condition on the breastfed infant.
Fertility.
Fluconazole had no effect on the fertility of male and female rats.
Effects on the ability to drive and operate machinery.
No studies have been conducted on the effect of fluconazole on the ability to drive or operate machinery.
Patients should be informed of the possibility of dizziness or seizures (see the “Side Effects” section) while taking this medication. If such symptoms develop, driving or operating machinery is not recommended.
Dosage and Administration
The drug should be taken by mouth. It may be taken with or without food.
Adults.
The drug is administered as a single 150 mg dose.
Elderly patients.
In the absence of signs of renal insufficiency, the standard adult dose should be used to treat this patient population.
Renal impairment.
Fluconazole is excreted primarily unchanged in the urine. For a single dose of fluconazole, no dose adjustment is required in this patient population.
Hepatic impairment.
Fluconazole should be used with caution in patients with hepatic impairment, as there is insufficient information regarding the use of fluconazole in this patient population (see the sections “Special Instructions and Precautions for Use” and “Side Effects”).
Children.
The efficacy and safety of the drug for the treatment of genital candidiasis in children have not been established, despite extensive data on the use of fluconazole in children. If there is an urgent need to use the drug in adolescents (ages 12 to 17), the usual adult doses should be used.
Overdose
Symptoms: hallucinations and paranoid behavior.
Treatment: symptomatic (including gastric lavage and supportive care). Fluconazole is excreted primarily in the urine; therefore, forced diuresis may accelerate the drug’s elimination. A 3-hour hemodialysis session reduces plasma fluconazole levels by approximately 50%.
Side Effects
Drug-induced reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of fluconazole has been reported (see Section 4.4).
The most common adverse reactions (occurring in ≥1/100 to <1/10 of patients) were: headache, abdominal pain, diarrhea, nausea, vomiting, elevated levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase, and rash
The following classification is used to assess the frequency of adverse reactions: very common (≥1/10), common (from ≥1/100 to <1/10), uncommon (from ≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), frequency unknown (cannot be estimated from the available data).
Blood and lymphatic system disorders.
Uncommon: anemia.
Rare: agranulocytosis, leukopenia, neutropenia, thrombocytopenia.
Immune system disorders.
Rare: anaphylaxis.
Metabolic and nutritional disorders.
Uncommon: decreased appetite.
Rare: hypertriglyceridemia, hypercholesterolemia, hypokalemia.
Psychiatric disorders.
Uncommon: insomnia, drowsiness.
Nervous system disorders.
Common: headache.
Uncommon: seizures, dizziness, paresthesia, taste disturbances.
Rare: tremor.
Hearing and balance disorders.
Uncommon: dizziness.
Cardiac disorders.
Rare: paroxysmal ventricular tachycardia of the “pirouette” type, QT interval prolongation (see the “Special Instructions and Precautions for Use” section).
Gastrointestinal disorders.
Common: abdominal pain, diarrhea, nausea, vomiting.
Uncommon: constipation, dyspepsia, flatulence, dry mouth.
Hepatobiliary disorders.
Common: elevated levels of ALT, AST, and alkaline phosphatase in the blood (see section “Special Instructions and Precautions for Use”).
Uncommon: cholestasis, jaundice, elevated bilirubin (see Section 4.4).
Rare: liver failure, hepatocellular necrosis, hepatitis, hepatocellular lesions (see section “Special Instructions and Precautions for Use”).
Skin and subcutaneous tissue disorders.
Common: rash (see section “Special Instructions and Precautions for Use”).
Uncommon: pruritus, drug-induced dermatitis (including fixed drug eruption), urticaria, increased sweating (see the section “Special Instructions and Precautions for Use”).
Rare: toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, angioedema, facial edema, alopecia (see the “Special Instructions and Precautions for Use” section).
Frequency unknown: drug reaction with eosinophilia and systemic symptoms (DRESS).
Musculoskeletal and connective tissue disorders.
Uncommon: myalgia.
General disorders and administration site conditions.
Uncommon: fatigue, malaise, asthenia, fever.
Children
The frequency and nature of adverse reactions and laboratory abnormalities in children, as recorded during clinical trials—with the exception of genital candidiasis—are comparable to those in adults.
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after a drug has been approved is an important procedure. It allows for continued monitoring of the benefit-risk profile of the drug. Healthcare professionals should report all suspected adverse reactions through the national reporting system and to the marketing authorization holder via the feedback form on the website: https://kusum.ua/pharmacovigilance/
Shelf Life
3 years.
Storage conditions
Store at a temperature not exceeding 25 °C
Keep out of reach of children.
Packaging
1 tablet per blister pack; 1 blister pack per cardboard box.
Sales Conditions
Available without a prescription.
Manufacturer
KUSUM HEALTHCARE PVT LTD/
KUSUM HEALTHCARE PVT LLC
Manufacturer’s location and address.
SP-289 (A), RIICO Industrial Zone, Chopanki, Bhiwadi, Alwar District (Rajasthan), India/
SP-289 (A), RIICO Industrial Zone, Chopanki, Bhiwadi, Alwar District (Rajasthan), India.
Address
SP-289 (A), RIICO Industrial Zone, Chopanki, Bhiwadi, Alwar District (Rajasthan), India/
SP-289 (A), RIICO Industrial Zone, Chopanki, Bhiwadi, Alwar District (Rajasthan), India.
Similar products
Products from the same category











